Correlation between voriconazole trough plasma concentration and hepatotoxicity in patients with different CYP2C19 genotypes

Kazuaki Matsumoto, Kazuro Ikawa, Kazuko Abematsu, Naoko Fukunaga, Kentaro Nishida, Tomohide Fukamizu, Yoshihiro Shimodozono, Norifumi Morikawa, Yasuo Takeda, Katsushi Yamada

Research output: Contribution to journalArticle

80 Citations (Scopus)

Abstract

Voriconazole metabolism is mostly mediated via the cytochrome P450 (CYP) 2C19 isozyme. The non-wild (mutant) type of CYP2C19 is generally found in 60-70% of Asian populations. Because the voriconazole trough plasma concentration has been reported to correlate with hepatotoxicity, this study investigated the effect of CYP2C19 polymorphism on the relationship between voriconazole trough concentrations and liver function abnormalities in 29 Japanese patients with fungal infections (CYP2C19 wild-type, n = 10; non-wild-type, n = 19). Hepatotoxicity, defined as liver enzyme abnormality according to the National Cancer Institute criteria, was observed in 10 (34.5%) of 29 patients with a trough concentration ≥3.9 mg/L. Logistic regression analysis suggested that the therapeutic range for the voriconazole trough concentration should be 2-4 mg/L. Non-linear pharmacokinetic analysis suggested that voriconazole therapy should be initiated with a dose of 7.2-8.9 mg/kg/day for CYP2C19 wild-type and 4.4-6.5 mg/kg/day for the non-wild-type in Japanese patients. These recommended initial dosages and subsequent dose adjustment for the target concentration range by therapeutic drug monitoring should avoid adverse events and thus enable continued effective voriconazole therapy for Japanese patients with mycoses.

Original languageEnglish
Pages (from-to)91-94
Number of pages4
JournalInternational Journal of Antimicrobial Agents
Volume34
Issue number1
DOIs
Publication statusPublished - 2009 Jul
Externally publishedYes

Fingerprint

Genotype
Mycoses
National Cancer Institute (U.S.)
Drug Monitoring
Liver
Cytochrome P-450 Enzyme System
Isoenzymes
Cytochrome P-450 CYP2C19
Voriconazole
Therapeutics
Pharmacokinetics
Logistic Models
Regression Analysis
Enzymes
Population

Keywords

  • CYP2C19 polymorphism
  • Hepatotoxicity
  • Michaelis-Menten model
  • Therapeutic drug monitoring
  • Voriconazole

ASJC Scopus subject areas

  • Microbiology (medical)
  • Infectious Diseases
  • Pharmacology (medical)

Cite this

Correlation between voriconazole trough plasma concentration and hepatotoxicity in patients with different CYP2C19 genotypes. / Matsumoto, Kazuaki; Ikawa, Kazuro; Abematsu, Kazuko; Fukunaga, Naoko; Nishida, Kentaro; Fukamizu, Tomohide; Shimodozono, Yoshihiro; Morikawa, Norifumi; Takeda, Yasuo; Yamada, Katsushi.

In: International Journal of Antimicrobial Agents, Vol. 34, No. 1, 07.2009, p. 91-94.

Research output: Contribution to journalArticle

Matsumoto, Kazuaki ; Ikawa, Kazuro ; Abematsu, Kazuko ; Fukunaga, Naoko ; Nishida, Kentaro ; Fukamizu, Tomohide ; Shimodozono, Yoshihiro ; Morikawa, Norifumi ; Takeda, Yasuo ; Yamada, Katsushi. / Correlation between voriconazole trough plasma concentration and hepatotoxicity in patients with different CYP2C19 genotypes. In: International Journal of Antimicrobial Agents. 2009 ; Vol. 34, No. 1. pp. 91-94.
@article{5118a437126c4ed6a1e0a95dfdb9f3f7,
title = "Correlation between voriconazole trough plasma concentration and hepatotoxicity in patients with different CYP2C19 genotypes",
abstract = "Voriconazole metabolism is mostly mediated via the cytochrome P450 (CYP) 2C19 isozyme. The non-wild (mutant) type of CYP2C19 is generally found in 60-70{\%} of Asian populations. Because the voriconazole trough plasma concentration has been reported to correlate with hepatotoxicity, this study investigated the effect of CYP2C19 polymorphism on the relationship between voriconazole trough concentrations and liver function abnormalities in 29 Japanese patients with fungal infections (CYP2C19 wild-type, n = 10; non-wild-type, n = 19). Hepatotoxicity, defined as liver enzyme abnormality according to the National Cancer Institute criteria, was observed in 10 (34.5{\%}) of 29 patients with a trough concentration ≥3.9 mg/L. Logistic regression analysis suggested that the therapeutic range for the voriconazole trough concentration should be 2-4 mg/L. Non-linear pharmacokinetic analysis suggested that voriconazole therapy should be initiated with a dose of 7.2-8.9 mg/kg/day for CYP2C19 wild-type and 4.4-6.5 mg/kg/day for the non-wild-type in Japanese patients. These recommended initial dosages and subsequent dose adjustment for the target concentration range by therapeutic drug monitoring should avoid adverse events and thus enable continued effective voriconazole therapy for Japanese patients with mycoses.",
keywords = "CYP2C19 polymorphism, Hepatotoxicity, Michaelis-Menten model, Therapeutic drug monitoring, Voriconazole",
author = "Kazuaki Matsumoto and Kazuro Ikawa and Kazuko Abematsu and Naoko Fukunaga and Kentaro Nishida and Tomohide Fukamizu and Yoshihiro Shimodozono and Norifumi Morikawa and Yasuo Takeda and Katsushi Yamada",
year = "2009",
month = "7",
doi = "10.1016/j.ijantimicag.2009.01.008",
language = "English",
volume = "34",
pages = "91--94",
journal = "International Journal of Antimicrobial Agents",
issn = "0924-8579",
publisher = "Elsevier",
number = "1",

}

TY - JOUR

T1 - Correlation between voriconazole trough plasma concentration and hepatotoxicity in patients with different CYP2C19 genotypes

AU - Matsumoto, Kazuaki

AU - Ikawa, Kazuro

AU - Abematsu, Kazuko

AU - Fukunaga, Naoko

AU - Nishida, Kentaro

AU - Fukamizu, Tomohide

AU - Shimodozono, Yoshihiro

AU - Morikawa, Norifumi

AU - Takeda, Yasuo

AU - Yamada, Katsushi

PY - 2009/7

Y1 - 2009/7

N2 - Voriconazole metabolism is mostly mediated via the cytochrome P450 (CYP) 2C19 isozyme. The non-wild (mutant) type of CYP2C19 is generally found in 60-70% of Asian populations. Because the voriconazole trough plasma concentration has been reported to correlate with hepatotoxicity, this study investigated the effect of CYP2C19 polymorphism on the relationship between voriconazole trough concentrations and liver function abnormalities in 29 Japanese patients with fungal infections (CYP2C19 wild-type, n = 10; non-wild-type, n = 19). Hepatotoxicity, defined as liver enzyme abnormality according to the National Cancer Institute criteria, was observed in 10 (34.5%) of 29 patients with a trough concentration ≥3.9 mg/L. Logistic regression analysis suggested that the therapeutic range for the voriconazole trough concentration should be 2-4 mg/L. Non-linear pharmacokinetic analysis suggested that voriconazole therapy should be initiated with a dose of 7.2-8.9 mg/kg/day for CYP2C19 wild-type and 4.4-6.5 mg/kg/day for the non-wild-type in Japanese patients. These recommended initial dosages and subsequent dose adjustment for the target concentration range by therapeutic drug monitoring should avoid adverse events and thus enable continued effective voriconazole therapy for Japanese patients with mycoses.

AB - Voriconazole metabolism is mostly mediated via the cytochrome P450 (CYP) 2C19 isozyme. The non-wild (mutant) type of CYP2C19 is generally found in 60-70% of Asian populations. Because the voriconazole trough plasma concentration has been reported to correlate with hepatotoxicity, this study investigated the effect of CYP2C19 polymorphism on the relationship between voriconazole trough concentrations and liver function abnormalities in 29 Japanese patients with fungal infections (CYP2C19 wild-type, n = 10; non-wild-type, n = 19). Hepatotoxicity, defined as liver enzyme abnormality according to the National Cancer Institute criteria, was observed in 10 (34.5%) of 29 patients with a trough concentration ≥3.9 mg/L. Logistic regression analysis suggested that the therapeutic range for the voriconazole trough concentration should be 2-4 mg/L. Non-linear pharmacokinetic analysis suggested that voriconazole therapy should be initiated with a dose of 7.2-8.9 mg/kg/day for CYP2C19 wild-type and 4.4-6.5 mg/kg/day for the non-wild-type in Japanese patients. These recommended initial dosages and subsequent dose adjustment for the target concentration range by therapeutic drug monitoring should avoid adverse events and thus enable continued effective voriconazole therapy for Japanese patients with mycoses.

KW - CYP2C19 polymorphism

KW - Hepatotoxicity

KW - Michaelis-Menten model

KW - Therapeutic drug monitoring

KW - Voriconazole

UR - http://www.scopus.com/inward/record.url?scp=67349258906&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=67349258906&partnerID=8YFLogxK

U2 - 10.1016/j.ijantimicag.2009.01.008

DO - 10.1016/j.ijantimicag.2009.01.008

M3 - Article

VL - 34

SP - 91

EP - 94

JO - International Journal of Antimicrobial Agents

JF - International Journal of Antimicrobial Agents

SN - 0924-8579

IS - 1

ER -